June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
|Articles|May 17, 2019
When to consider corneal cross-linking treatment
Author(s)Julianne Mobilian
Audrey Talley Rostov, MD, discusses corneal cross-linking (CXL) complications, and when to consider CXL treatment
Advertisement
Advertisement
Related to this article
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
Length and width, not thickness, emerge as key drivers of higher-order aberrations.
A prospective pilot series finds Keraring implantation cuts refractive cylinder by 61% in non-ectatic corneas, opening a new conversation about ICRS indications.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
2
Matching artificial tears to dry eye phenotype: a Q&A with Omur Ucakhan, MD
3
Demodex blepharitis: Diagnosis, treatment response, and recurrence
4
Myopia control using spectacle lenses with highly aspherical lenslets
5